OpenSAFELY: The impact of COVID-19 on azathioprine, leflunomide and methotrexate monitoring, and factors associated with change in monitoring rate.
Brown AD, Fisher L, Curtis HJ, Wiedemann M, Hulme WJ, Speed V, Hopcroft LEM, Cunningham C, Costello RE, Galloway JB, Russell MD, Bechman K, Kurt Z, Croker R, Wood C, Walker AJ, Schaffer AL, Bacon SCJ, Mehrkar A, Hickman G, Bates C, Cockburn J, Parry J, Hester F, Harper S, Goldacre B; OpenSAFELY Collaborative; MacKenna B.
Brown AD, et al. Among authors: wood c.
Br J Clin Pharmacol. 2024 Apr 8. doi: 10.1111/bcp.16062. Online ahead of print.
Br J Clin Pharmacol. 2024.
PMID: 38589944